The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Denali Therapeutics Inc shares valued at $7,429,230 were sold by Watts Ryan J. on Jul 09 ’25. At $15.00 per share, Watts Ryan J. sold 495,282 shares. The insider’s holdings dropped to 253,071 shares worth approximately $3.68 million following the completion of this transaction.
Also, Watts Ryan J. purchased 495,282 shares, netting a total of over 7,097,391 in proceeds.
Before that, Ho Carole had sold 12,255 shares from its account. In a trade valued at $247,796, the Chief Medical Officer traded Denali Therapeutics Inc shares for $20.22 each. Upon closing the transaction, the insider’s holdings decreased to 12,255 shares, worth approximately $2.59 million.
As published in a research note from Cantor Fitzgerald on April 10, 2025, Denali Therapeutics Inc [DNLI] has been rated up from a Neutral to an Overweight. As of February 11, 2025, Deutsche Bank has initiated its “Buy” rating for DNLI. Earlier on January 07, 2025, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for DNLI stock.
Analyzing DNLI Stock Performance
On last trading session,, Denali Therapeutics Inc [NASDAQ: DNLI] plunged -2.29% to $14.53. The stock’s lowest price that day was $14.4, but it reached a high of $15.15 in the same session. During the last five days, there has been a drop of approximately -5.34%. Over the course of the year, Denali Therapeutics Inc shares have dropped approximately -37.72%.
Support And Resistance Levels for Denali Therapeutics Inc (DNLI)
RSI (Relative Strength Index) is 50.58 on the 14-day chart, showing neutral technical sentiment.
Is Denali Therapeutics Inc subject to short interest?
Stocks of Denali Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.15 million shares to 11.95 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 12.1 million shares. A decline of -1.3% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.92 of the overall float, the days-to-cover ratio (short ratio) decline to 7.92.
Which companies own the most shares of Denali Therapeutics Inc (DNLI)?
In terms of Denali Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 33 in the next 12 months, up nearly 121.92% from the previous closing price of $14.87. Analysts anticipate Denali Therapeutics Inc stock to reach 70 by 2025, with the lowest price target being 22. In spite of this, 4 analysts ranked Denali Therapeutics Inc stock as Buy at the end of 2025.
